Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (F

Social Author Image
https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg
Tweet Author
RichardPAConway
Social Author Name
Richard Conway
Tweet Content
Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR
Links
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primar… https://acrabstracts.org/abstract/efficacy-and-safety-of-nipocalimab-an-anti-fc…
https://x.com/RichardPAConway/status/1858513994107297997/photo/1
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×